Investigating Mucinase Activity in Airway Disease
The purpose of this study is to investigate how mucus (phlegm or spit) is broken down once it forms in the airways (bronchial tubes) of people with lung disease. This research study will also examine whether blood groups have an effect on lung function or the type of mucus found in the lung. This study is not designed to be a treatment for asthma, emphysema, cystic fibrosis, or other lung disease. It is designed to help the investigators learn more about the causes of airway disease.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Investigating Mucinase Activity in Airway Disease|
- rheological measurements (viscosity and elasticity) in sputum. [ Time Frame: 2-3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||April 2003|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
People who have been diagnosed with Asthma
People who have been diagnosed with Cystic Fibrosis
People who either have a history of cigarette smoking of at least 10 pack years and current smoking of at least 10 cigarettes a day, or have a history of cigarette smoking of at least 10 pack years and FEV1/FVC ratio less than 0.7.
People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
Accumulation of mucus in the airway involves the process of overproduction and reduced clearance of mucin glycoproteins. To date, little attention has been focused on mechanisms of mucin clearance from the airway. We hypothesize that there is enzymatic degradation of mucins ("mucinase activity") in the airway, which acts to break down mucins and facilitate their clearance. We further hypothesize that glycosidases function as mucinases by removing peripheral monosaccharides from oligosaccharides, including oligosaccharides on mucins. Removal of terminal or capping sugars on mucin side chains may be an important mechanism in mucin degradation and clearance from the lung. If mucinase activity exists in the airway then mucus collected from human subjects should demonstrate evidence of mucin degradation ex vivo, especially at 37ºC. As part of our protocol we propose to examine changes in airway mucus ex vivo under different experimental conditions. Our primary readout will be measures of sputum rheology, namely viscosity and elasticity. Our consultant for this methodology will be Dr Susan Muller (Chemical Engineering, UC Berkeley). In order to conduct experimental studies in this way we will need multiple samples from the same subjects. Thus, up to 10 or more sputum samples per subject will be collected on different days. In addition, we are interested in the biochemical properties of sputum and saliva, specifically the composition of mucin molecules found in these fluids.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596232
|Contact: Kelly Norsworthy, BAemail@example.com|
|United States, California|
|UCSF Airway Clinical Research Center||Recruiting|
|San Francisco, California, United States, 94143|
|Contact: Kelly Norsworthy, BA 415-502-8791 firstname.lastname@example.org|
|Principal Investigator:||John V Fahy, M.D., M.Sc.||University of California, San Francisco|